U.S. markets close in 2 hours 25 minutes

  • S&P 500

    3,718.82
    +18.17 (+0.49%)
     

  • Dow 30

    30,363.25
    +139.36 (+0.46%)
     

  • Nasdaq

    12,775.60
    +77.15 (+0.61%)
     

  • Russell 2000

    1,981.61
    +35.70 (+1.83%)
     

  • Crude Oil

    50.11
    +2.49 (+5.23%)
     

  • Gold

    1,954.20
    +7.60 (+0.39%)
     

  • Silver

    27.64
    +0.28 (+1.01%)
     

  • EUR/USD

    1.2302
    +0.0048 (+0.39%)
     

  • 10-Yr Bond

    0.9580
    +0.0410 (+4.47%)
     

  • GBP/USD

    1.3620
    +0.0043 (+0.32%)
     

  • USD/JPY

    102.6710
    -0.4300 (-0.42%)
     

  • BTC-USD

    33,098.61
    +383.02 (+1.17%)
     

  • CMC Crypto 200

    633.76
    +36.32 (+6.08%)
     

  • FTSE 100

    6,612.25
    +40.37 (+0.61%)
     

  • Nikkei 225

    27,158.63
    -99.75 (-0.37%)
     

Some Florida counties are using Eventbrite to schedule COVID-19 vaccines

Kris Holt
·Contributing Writer
·2 min read

States are taking charge of COVID-19 vaccine distribution rather than the federal government, but some don't have a statewide plan and are leaving it up to counties. To help manage appointment scheduling, several counties in Florida have turned to ticketing services like Eventbrite, as The Verge reports.

For the time being, those in Brevard County who are currently eligible for a vaccine (health care workers, long-term care facility residents and those over 65) have to use Eventbrite to schedule an appointment. The county's health department switched to an online approach after residents overwhelmed a hotline.

There are some concerns with such systems, however. Residents who are used to booking tickets for shows through online platforms may find it easier to lock in a vaccination time than those who aren't. Within a day of Brevard County's Eventbrite system getting off the ground, residents had snapped up all of the appointments for the first vaccine shipment.

Residents who don't have internet access may find it difficult to claim a vaccination slot, perhaps leaving vulnerable individuals at risk, while reports have emerged of fake Eventbrite accounts charging for appointments. It's also possible that a gray market for vaccine slots will bubble up if bots are able to lock in appointments faster than people can, but there's no evidence of that happening yet, according to StateScoop.

Although health authorities have had months to prepare for distribution, officials told The Verge that opting for an online ticketing system was the easiest way to ramp up vaccination programs quickly. One in Brevard County said the approach had worked well so far and that residents, on the whole, found the approach to be easy. The health department plans to keep using Eventbrite for its next shipment, and it hopes to have its hotline back in operation by then.

Latest Stories

  • Tesla’s Downgrade, Snowflake’s Lockup, and QuantumScape’s Stunning Selloff

    Investors hoping for a quick bounce in the stock market following Monday’s drubbing will be disappointed by action in the futures market this morning.

  • Joe Biden now says he wants to give you a third stimulus check — for $2,000

    Here's how the president-elect says $2,000 payments could "go out the door immediately."

  • Alibaba Shares Leap After CNBC Reports Billionaire Founder Jack Ma 'Not Missing'

    Alibaba's billionaire co-founder, Jack Ma, is not 'missing', CNBC reported Tuesday, after drawing the ire of the Chinese leadership for critical comments he made during a speech in October.

  • Stimulus: IRS 'Get My Payment' tracking tool now working for $600 direct payments

    Americans can now check the status of their second stimulus check using the Internal Revenue Service’s online tracking tool.

  • Pfizer Drops the Big Blue Pill to Highlight Shift in Strategy

    (PFE)is dropping the big blue pill for something a bit more… science-y. The rebranding comes as Pfizer (ticker: PFE) completes a slimming-down that has seen it shed a range of businesses, to focus almost entirely on inventing and buying new drugs. The turn away from the big blue pill also, incidentally, comes months after the company spun off the division that sells Viagra, Pfizer’s “little blue pill.”

  • Billionaire Carl Icahn says he’s well hedged ahead of a potential ‘painful correction’ for the stock market

    KEY WORDS That’s billionaire investor Carl Icahn talking to CNBC during Monday’s selloff about the potential for a big drop in the stock market. “Another thing they have in common is it’s always said, ‘it’s different this time,'” he continued.

  • 2 “Strong Buy” Penny Stocks That Could Deliver Massive Returns

    There’s a strong feeling growing among investors – of relief – that the new year will feature lower volatility than 2020. That along would be enough to boost spirits, but better yet, there is also a perception that the markets are going to drive higher in the new year.Marko Kolanovic, JPMorgan’s well-known quant expert, sees the initial stages of a positive feedback loop, with lower volatility and systematic investment strategies coming together to drive gains, attracting more investors – and, in Kolanovic’s view, pushing the S&P 500 to 4,600 by year’s end. That will be a 25% increase for the index.A general market environment like that is bound to produce plenty of stock winners, and Wall Street’s analysts are busy pointing them out. Among other things, they are tapping penny stocks, equities priced at less than $5 per share. Their rock-bottom starting price makes pennies the logical place to look for huge returns on investment. Although their risk factor is high, even a small gain in absolute numbers will turn into a massive percentage gain in share price.Using TipRanks’ database, we identified two penny stocks the pros believe could see explosive gains in the coming months. Not to mention each one gets a “Strong Buy” consensus rating from the analyst community.9 Meters Biopharma (NMTR)Some biopharma companies take a broad-based approach, while others focus on a niche. 9 Meters is one of the latter, taking aim at unmet needs for gastrointestinal patients. The company’s development pipeline features drug candidates under investigation as treatments for short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat.Drilling down to pipeline details, 9 Meters’ flagship product, Larazotide, is in Phase 3 development for the treatment of CeD. CeD affects about 1% of the population, yet there are no approved therapies. Top-line data from the study is expected in the second half of 2021.Furthermore, this past December, the company announced that it had entered an agreement with EBRIS, the European Biomedical Research Institute of Salerno, to investigate Larazotide as a potential treatment for respiratory complications due to COVID-19.The other major drug in the company’s pipeline is NM-002, for SBS. The company has recently announced positive Phase 1b/2a results, with a measurable impact on disease symptoms from a compound that was well-tolerated by patients.NMTR’s strong pipeline and $0.89 share price have scored it substantial praise from the pros on Wall Street.One of these NMTR bulls is Truist’s Srikripa Devarakonda. Citing Larazotide as a key component of his bullish thesis, the analyst noted, “We acknowledge investors are likely to see a pivotal trial in a tough-to-crack Celiac disease program as high risk despite encouraging Ph2b data. We model $705M/$353M in peak unadjusted/adjusted sales and see potential upside of 400% - 1650% from positive Ph3 readout.”Devarakonda also sees “significant unmet need in SBS” and continues to believe that “NM-002 has a differentiated profile vs. SOC.” His key takeaways from the recent Phase 1b/2a results include: “1) we believe that the drug showed early activity in SBS patients; all 9 patients showed meaningful reduction in total stool output volume; average TSO reduction was 42% from baseline; 2) responses occur rapidly, with effects on TSO seen within 48 hours of dosing; 3) safety profile looks favorable, we would like to see greater durability.”To this end, Devarakonda rates NMTR shares a Buy along with a $5 price target. This figure conveys his confidence in NMTR’s ability to soar 462% in the coming year. (To watch Devarakonda’s track record, click here)Turning now to the rest of the Street, other analysts are on the same page. With 4 Buys and no Holds or Sells, the word on the Street is that NMTR is a Strong Buy. Given its $4.33 average price target, upside of 386% could be in store for investors. (See NMTR stock analysis on TipRanks)Orchard Therapeutics (ORTX)Orchard Therapeutics takes the broad-based approach to the biopharma industry. The company is engaged in the development of gene therapies for rare, frequently terminal, diseases, including neurometabolic disorders, primary immune deficiencies, and blood disorders. The gene therapy approach uses blood stem cells to deliver corrected genetic information directly into the patient’s body.Orchard’s pipeline demonstrates the diversity of disorders amenable to gene therapy – the company has no less than 12 drug candidates in development. Among these candidates, Libmeldy (OTL-200) stands out.Libmeldy is in commercialization stages as a treatment for MLD (metachromatic leukodystrophy), a rare, mutation-based genetic disorder of the nervous system. Libmeldy, which is designed to treat children suffering from the infantile for juvenile forms of MLD by replacing the defective ARSA gene, received its approval for medical use in the EU in December 2020.Wedbush analyst David Nierengarten notes the European approval of Libmeldy, and its implication for Orchard’s progress. He writes, “We look forward to the company’s commercial execution in the EU and an eventual 2022 approval in the US. Last month ORTX received IND clearance from the FDA for the program paving the way for discussions with the US regulators to decide a suitable path forward toward a BLA filing.”"Net-net, with possibly two gene therapies approved in the next 12-18 months and a pivotal study beginning in a third (MPS-I), we think ORTX shares are undervalued at these levels," the analyst concluded. In line with his bullish comments, Nierengarten rates ORTX as Outperform (i.e. Buy), and his $15 price target indicates a potential for 241% growth in the year ahead. (To watch Nierengarten’s track record, click here)Do other analysts agree with Nierengarten? They do. Only Buy ratings, 3, in fact, have been issued in the last three months. Therefore, ORTX gets a Strong Buy consensus rating. At $15, the average price target indicates shares could appreciate by 241% in the year ahead. (See ORTX stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • 3 Stocks Trading at Rock-Bottom Prices; Analysts Say ‘Buy’

    A new year, a new addition to the stock portfolio – what can make more sense than that? The right time to buy, of course, is when stocks are priced at the bottom. Buying low and selling high may be a bit hackneyed, but it’s true, and truth has staying power.But the markets are up. The NASDAQ rose 43% in 2020, and the S&P 500 showed a gain of 16%. With a market environment like that, finding stocks that are caught in the doldrums is harder than it looks. That's where the Wall Street pros can lend a hand.We used TipRanks' database to pinpoint three stocks that fit a profile: a share price that has dropped over 30% in the last 12 months, but with at least double-digit upside potential, according to analysts. Not to mention each has earned a Moderate or Strong Buy consensus rating.Esperion (ESPR)We will start with Esperion, a company that specializes in therapies for the treatment of elevated low-density lipoprotein cholesterol levels – a major factor contributing to heart disease. The company’s main product, bempedoic acid, is now available in tablet form under the brand names Nexletol and Nexlizet.In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. The trial, called CLEAR Outcomes, is a large-scale, long-term study, tracking more than 14,000 patients with top-line data expected in the second half of 2022. The study covers 1,400 locations in 32 countries around the world.Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. Along with the drop in share value, the company showed a fall in revenue from Q2 to Q3, with the top line collapsing from $212 million to $3.8 million. Since the Q3 report, Esperion announced pricing on a $250 million offer of senior subordinated notes, at 4%, due in 2025. The offering gives the company a boost in available capital for further work on its development pipeline and its marketing efforts for bempedoic acid.Chad Messer, covering ESPR for Needham, sees the note offering as a net positive for Esperion. “We believe this cash position will be sufficient to support Esperion through 2021 and to profitability in 2022... We believe this financing should help put to rest concerns regarding Esperion's balance sheet. Despite a challenging launch for NEXLETOL and NEXLIZET, product growth has continued in 3Q against the backdrop of a contracting LDL-C market. This growth trajectory suggests potential for a rapid acceleration when conditions improve," Messer wrote.To this end, Messer rates ESPR shares a Strong Buy, and his price target, at $158, suggests the stock has room for huge growth this year – up to 481% from current levels. (To watch Messer’s track record, click here)Overall, Esperion has 6 recent reviews on record, with a breakdown of 5 Buys and 1 Hold to give the stock a Strong Buy rating from the analyst consensus. The shares, trading at $27.16, have an average price target of $63.33, implying a one-year upside of 133%. (See ESPR stock analysis on TipRanks)Intercept Pharma (ICPT)Liver disease is a serious health threat, and Intercept Pharma is focused on developing treatments for some of the more dangerous chronic liver conditions, including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Intercept has a research pipeline based on FXR, a regulator of bile acid pathways in the hepatic system.FXR’s action affects not just the bile acid metabolism, but also the glucose and lipid metabolisms, and inflammation and fibrosis around the liver. The lead compound, obeticholic acid (OCA), is an analog of the bile acid CDCA, and as such can take a role in the FXR pathways and receptors implicated in chronic liver disease. Treating liver disease through the FXR biology has direct applications for PBC, and is showing promise treating complications from NASH.ICPT shares dropped sharply last summer, when the FDA rejected the company’s application to approve OCA for treatment of NASH-related liver fibrosis. This delays the drug’s potential entry to a lucrative market; there is no current treatment for NASH, and the first drug to win approval will have the lead in reaching a market estimated at $2 billion to $5 billion in potential annual sales. The effect on the stock is still felt, and ICPT remains at its 52-week low point.In reaction, in December of 2020, Intercept announced major changes in top-level management, as CEO and President Mark Pruzanski announced he's stepping down effective January 1 of this year. He is succeeded by Jerome Durso, formerly the company’s COO, who will also take a post on the Board of Directors. Pruzanski will remain as an advisor, and will hold a director’s position on the company’s Board.Piper Sandler analyst Yasmeen Rahimi takes a deep dive into Intercept’s continuing efforts to expand applications of OCA and to resubmits its New Drug Application to the FDA. She sees the leadership transition as part of these efforts, and writes, “[We] believe that Dr. Pruzanski's dedication to transform the liver space is still strong, and that he will continue to guide ICPT's progress as an advisor and Board member. Additionally, we have had the pleasure of working closely with Jerry Durso and believe that he will transform the company and lead ICPT's success in growing the PBC market and the path to potential approval and commercial launch of OCA in NASH.”Rahimi takes a long-term bullish stance on ICPT, giving the stock an Overweight (i.e. Buy) rating and an $82 price target. This figure indicates an impressive 220% upside for the next 12 months. (To watch Rahimi’s track record, click here)Wall Street is somewhat more divided on the drug maker. ICPT's Moderate Buy consensus rating is based on 17 reviews, including 8 Buys and 9 Holds. Shares are priced at $25.82, and the average price target of $59.19 suggests an upside potential of 132% for the next 12 months. (See ICPT stock analysis on TipRanks)Gilead Sciences (GILD)Gilead has had a year like a firework – fast up and fast down. The gains came in 1H20, when it appeared that the company’s antiviral drug remdesivir would become a prime treatment for COVID-19. By November, however, even though remdesivir had been approved, the World Health Organization (WHO) was recommending against its use, and the COVID vaccines now on the market have made remdesivir irrelevant to the pandemic.This was only one of Gilead’s recent headwinds. The company has been working, in conjunction with Galapagos (GLPG), on development of filgotinib as a treatment for rheumatoid arthritis. While the drug received EU and Japanese approval in September 2020, the FDA has withheld approval and Gilead announced in December that it was suspending US development efforts on the drug.Even so, Gilead retains a diverse and active research pipeline, with over 70 research candidates at varying stages of the development and approval process for a wide range of diseases and conditions, including HIV/AIDS, inflammatory & respiratory diseases, cardiovascular disease, and hematology/oncology.On a positive note, Gilead posted Q3 earnings above estimates, with the top line revenue, of $6.58 billion, beating the forecast by 6% and growing 17% year-over-year. The company updated its full-year 2020 guidance on product sales from $23 billion to $23.5 billion.Among the bulls is Oppenheimer analyst Hartaj Singh, who gives GILD shares an Outperform (i.e. Buy) rating and $100 price target. Investors stand to pocket a 69% gain should the analyst’s thesis play out. (To watch Singh’s track record, click here)Backing his stance, Singh writes, “We continue to believe in our thesis of (1) a dependable remdesivir/other medicines business against SARS-CoV flares, (2) a base business (HIV/oncology/HCV) growing low-single digits over the next couple of years, (3) operating leverage providing greater earnings growth, and (4) a 3-4% dividend yield.” What does the rest of the Street think? Looking at the consensus breakdown, opinions from other analysts are more spread out. 10 Buys, 12 Holds and 1 Sell add up to a Moderate Buy consensus. In addition, the $73.94 average price target indicates 25% upside potential from current levels. (See GILD stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • CEO of Bill Gates-backed electric car battery startup comments on company outlook after stock plunges 40%

    QuantumScape founder Jagdeep Singh talks with Yahoo Finance after the company's stock fell 40% Tuesday morning.

  • It's no surprise that Amazon, Berkshire, JPM health venture Haven is disbanding: Experts

    The news that Haven, the joint health-care venture between Amazon, will disband next month came as no surprise to many health-care experts.

  • Georgia Runoff Elections Have Huge Implications For Stock Market Outlook

    A Democrat victory in both Georgia runoff elections could have huge implications for tax and spending policy, the shape of the coronavirus recovery and the stock market outlook.

  • QuantumScape’s CEO Talked About the Stock’s 40% Drop. A Clear Reason Is Hard to Find.

    QuantumScape CEO Jagdeep Singh appeared on CNBC Monday evening. The company’s 40% stock drop came up. Here’s what he said.

  • Social Security, Medicare and Retirement Plan Changes for 2021

    Here's everything you need to know about Social Security raises, cost for Medicare premiums and retirement plan limits for 2021.

  • Merck Stock Is Deeply Undervalued, Says Citi. It Could Surge in 2021.

    Merck stock slumped 11% last year, lagging both the pharma sector and broader market. Citi analyst Andrew Baum rates shares at Buy and sees them rising 31%.

  • I Dislike Picking a Top Pick for the Year, but Here Is Mine for 2021

    It's a stock that underperformed the last two years but would likely excel in a year of renewed growth in economic activity.

  • Is Apple Stock A Buy Right Now? Here's What IBD Charts Show

    Apple has been an American success story several times over with the Mac, iPod, iPhone and other inventions. But is Apple stock a buy now? Here's what its stock chart and earnings show.

  • Investors are waiting for ‘cash on the sidelines’ to juice the stock market — this is why that idea is hogwash

    Lance Roberts explains why money won't soon pour into the stock market from bank and money market accounts.

  • Is Ford Stock A Buy Now As Earnings Rebound?

    Long-ailing Ford faces new coronavirus challenges with demand and supply chains. But is Ford primed for a comeback? Here’s what you should know.

  • Here’s how bitcoin could soon be worth $146,000 according to JPMorgan

    JPMorgan researchers point to outflows from gold-pegged exchange traded funds, or ETFs, and inflows into a digital-currency focused trusts sponsored by Grayscale, for example, as part of the evidence pointing to increased use of bitcoin as a gold-like asset, which would help to drive its price further into the stratosphere.

  • A $13 Trillion Debt Bill Comes Due for Big Economies

    (Bloomberg) -- The world’s biggest economies shouldering record debt burdens are about to confront an unwelcome legacy of the financial crisis: a $13 trillion debt bill.The Group of Seven nations plus key emerging markets face the heaviest bond maturities in at least a decade, much of them borrowings to dig their economies out of the worst slump since the Great Depression. According to data compiled by Bloomberg, these governments may need to roll over 51% more debt than in 2020.The good news is that both central banks and investors are on their side. Policy makers facing lingering economic challenges from the pandemic are likely to stay accommodative -- and keep borrowing costs low. Bonds remain a sought-after haven amid the virus’s rising toll on health and economies.”Government debt ratios have exploded, but I believe that the short-term worrying over a rising debt is fruitless,” said Gregory Perdon, co-chief investment officer at Arbuthnot Latham. “Debt is leverage and assuming it’s not abused, it’s one of the most successful tools for growing wealth.”Refinancing needs are the biggest in the U.S., with $7.7 trillion of debt coming due, followed by Japan with $2.9 trillion, according to Bloomberg data. China’s tab rises to $577 billion from $345 billion last year. In Europe, Italy has the heaviest bill of $433 billion, followed by France’s $348 billion. Germany has $325 billion due versus $201 billion last year. Not all these maturities will necessarily be extended by fresh borrowings.To be sure, growth lift-off is still expected to translate into higher yields, with the median of economists surveyed by Bloomberg calling for a 10-year Treasury yield of 1.24% by the fourth quarter, from 0.93% currently. Yet the onus remains on the world’s policy makers to keep rates low to foster the global economic recovery. The Federal Reserve is on pace to buy nearly half the $2 trillion of net supply TD Securities expects the U.S. government debt to issue this year.In Europe, the result of central bank bond buying will help create a supply shortfall of 133 billion euros ($164 billion), according to Jefferies International.“The practical reality is that debt levels and rates are linked, because most of the developed world cannot afford higher interest rates,” said Steven Major, the global head of fixed income research at HSBC Holdings Plc.Read more: Ultra-Low Interest Rates Here to Stay: 2021 Central Bank Guide(Adds 10-year Treasury yield in sixth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.